At IOMED we are proud to announce the results of our independent Social Impact Report for 2023, verified by EQA last May, 2024. Thanks to our advanced platform for health data activation, we’ve revolutionized clinical research.

During the past year, we have actively participated in 25 research projects, processing and structuring clinical data in the OMOP (Observational Medical Outcomes Partnership) standard, significantly improving the results of these clinical studies. Thus, our technology has positively impacted more than 450.000 patients.

‍

Gabriel Maeztu, MD, and founder of IOMED, stated: "Personally, I never imagined that we could achieve an annual direct impact on more than 450.000 unique patients. To put it into context, without our technology, an ambitious, multicentric study costing 20 times more, usually involves only around 700 unique patients."

‍

‍

Furthermore, it is estimated that the results of these studies could potentially benefit 5,428,255 people, as the information obtained can be applied to improve treatments and diagnoses across a wide variety of pathologies.

‍

"IOMED has the potential to transform the lives of millions more through advances in medical research. Therefore, we continue to work towards building a more sustainable and accessible healthcare future through data," added Rohit Mistry, CEO of IOMED.

‍

This work aligns with the European Health Data Space (EHDS) initiative, highlighting IOMED's commitment to interoperability and secondary use of data across Europe. This initiative further strengthens IOMED's social impact, positioning it as a key data mediator for a future where interoperability becomes a reality.

‍

‍

‍